Eli Lilly (LLY) announced the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea, or OSA, and obesity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’
- Eli Lilly rises 6.3%
- Early notable gainers among liquid option names on December 20th
- Novo Nordisk (NYSE:NVO) Slides as Weight-Loss Drug Trial Misses Expectations
- Morning Movers: Lilly rises, Novo Nordisk falls following CagriSema trial data